Scholars Academic Journal of Biosciences
Abbreviated Key Title: Sch Acad J Biosci
ISSN 2347-9515 (Print) | ISSN 2321-6883 (Online)
Journal homepage: https://saspublishers.com
NIH National Library of Medicine National Center for Biotechnology Information
NLM ID:101629416

Biochemistry

Exploring CRISPR Cloning and Beyond Through a Biochemical Lens in Genetic Biotechnology

Mariam[1*], Khizra Ikhlaq[2], Zulaikha Abid[3], Fatima Sahar Uraf Maryam[1], Syed Qasim Mehmood[4], Ahtasham Ahmad[5], Sohrab Anwar Abbasi[6], Imran Ali Sani[7], Muhammad Adeel[8]

[1]Department of Biochemistry, University of Agriculture Faisalabad, Punjab Pakistan
[2]Department of Applied Biological Science, Chulabhorn Research Institute, Thailand
[3]School of Mineral Processing and Bioengineering, Central South University, China
[4]Department of Pharmacy COMSATS University Islamabad, Abbottabad Campus, Pakistan
[5]Department of Medical Laboratory Technology, Riphah International University Faisalabad
[6]Department of Microbiology, Hazara University Mansehra, KPK, Pakistan
[7]Department of Biotechnology, Balochistan, University of Information Technology Engineering and Management Sciences, BUITEMS Quetta
[8]Riphah College of Rehabilitation and Allied Health Sciences, Riphah International University Faisalabad, Punjab Pakistan

DOI: https://doi.org/10.36347/sajb.2025.v13i07.001 | **Received:** 21.05.2025 | **Accepted:** 29.06.2025 | **Published:** 02.07.2025

***Corresponding author:** Mariam
Department of Biochemistry, University of Agriculture Faisalabad, Punjab Pakistan

Abstract

Review Article



Graphical Abstract

By offering a precise, effective, and adaptable method for genome editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has completely transformed genetic biotechnology. Through a biochemical lens that highlights the molecular complexities behind its methods and discoveries, this review explores the complex field of CRISPR cloning and its emerging frontiers. We examine the molecular underpinnings of target identification, protospacer adjacent motif (PAM) specificity, and Cas nuclease activation, starting with the groundbreaking discovery of CRISPR-Cas systems in bacterial adaptive immunity. Advances in CRISPR-based cloning techniques, such as the creation of synthetic guide RNAs, Cas variants with specific functions, and high-fidelity and base-editing systems that reduce off-target effects, are also examined in the study. The molecular dynamics of DNA-RNA-protein interactions during gene targeting, activation of DNA repair pathways, and epigenetic state regulation are given special attention. We investigate cutting-edge uses beyond traditional genome editing, including RNA-targeting Cas proteins (like Cas13), CRISPR-based diagnostics and treatments, CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa). Additionally covered is the incorporation of CRISPR with other biochemical technologies, such as gene drives, programmable transcription factors, and synthetic biology circuits. The field's increasing biochemical sophistication is

Citation: Mariam, Khizra Ikhlaq, Zulaikha Abid, Fatima Sahar Uraf Maryam, Syed Qasim Mehmood, Ahtasham Ahmad, Sohrab Anwar Abbasi, Imran Ali Sani, Muhammad Adeel. Exploring CRISPR Cloning and Beyond Through a Biochemical Lens in Genetic Biotechnology. Sch Acad J Biosci, 2025 Jul 13(7): 867-876.

highlighted by new developments like CRISPR-nanoparticle conjugates for targeted delivery and CRISPR screening platforms for functional genomics. In the end, this review emphasizes how a thorough biochemical comprehension of CRISPR systems is essential to maximizing their potential in environmental engineering, biotechnology, medicine, and agriculture. We hope to shed light on potential future possibilities and stimulate creative research at the nexus of molecular biology, chemistry, and synthetic genetics by placing CRISPR cloning inside a biochemical framework.

Keywords: CRISPR-Cas systems, Gene editing, CRISPR cloning, Molecular biology techniques, Biochemical mechanisms, Cas9 nuclease, Guide RNA (gRNA) design.

INTRODUCTION

From crude instruments to the revolutionary CRISPR-Cas systems that characterize the current genetic revolution, the history of genome editing is an engrossing tale of biochemical inventiveness (Ali *et al*., 2024). The discovery and application of restriction endonucleases, bacterial enzymes that could precisely cut DNA at particular regions, marked the beginning of the voyage in the 1970s. By enabling scientists to splice genes and clone DNA fragments, these molecular scissors signaled the beginning of recombinant DNA technology, which set the stage for contemporary genetic engineering (Alekseeva *et al*., 2023). Targeted investigations of gene function were made possible by the development of site-directed mutagenesis in the 1980s, which allowed for more intentional changes to DNA sequences. The discovery of CRISPR-Cas systems, which were initially a bacterial adaptive immunological mechanism but were later transformed into a flexible, easy-to-use, and extremely precise gene-editing tool, marked a real paradigm shift (Aslam *et al*., 2021). CRISPR's biochemistry, which is based on the Cas9 protein's RNA-guided DNA cleavage, ushered in a new era of precision genetics by making genome editing incredibly easy and broadening its uses in synthetic biology, scientific research, and agriculture. This revolution was not an instant phenomenon, rather, it was the result of decades of biochemical investigation, with each breakthrough building on the one before it to produce a versatile, widely accessible, and incredibly influential toolset that keeps pushing the limits of molecular biology (Madhiyazhagan *et al*., 2024).

Because it shows the molecular foundations governing the specificity, effectiveness, and utility of this revolutionary gene-editing tool, a biochemical viewpoint is essential for comprehending CRISPR cloning (Irfan *et al*., 2024). Fundamentally, CRISPR-Cas systems are enzyme-driven mechanisms that include a series of biomolecular interactions, including the ability of Cas proteins to precisely cleave nucleic acid strands, the identification of protospacer adjacent motifs (PAMs), and the hybridization of guide RNA with target DNA. The catalytic processes of Cas nucleases (such as Cas9, Cas12, and Cas13), their conformational dynamics upon DNA binding, and the allosteric control that governs their on-target vs off-target activity are all deciphered with the aid of biochemical insights (Nazipova *et al*., 2020). Engineering more precise and reliable CRISPR tools requires an understanding of these minute molecular intricacies, particularly for therapeutic applications where inadvertent alterations might be harmful. Furthermore, by choosing the best buffer conditions, forecasting enzyme-substrate kinetics, and designing guide RNAs with improved stability and cleavage efficiency, biochemical studies help to optimize in vitro cloning procedures (Albayati *et al*., 2024). A biochemical lens also highlights the system's shortcomings, such as guide RNA misfolding or nuclease degradation, and proposes changes to get around them, such as employing chemically modified RNAs or tailored Cas variants. In summary, CRISPR cloning's biochemistry is a cornerstone for both study and application as it is not only fundamental but also plays a key role in advancing genetic biotechnology.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has transformed synthetic biology and genetic engineering by providing a previously unheard-of degree of genome editing accuracy, ease of use, and versatility (Wang *et al*., 2025). CRISPR-Cas systems, particularly CRISPR-Cas9, were first obtained from a bacterial immune system and have quickly developed into essential instruments for genetic modification in a wide variety of species. CRISPR has made it possible to precisely target gene knockouts, insertions, and point mutations in genetic engineering, which has sparked advances in gene therapy, disease modeling, and agricultural biotechnology (Uddin *et al*., 2020). It has significantly accelerated the development of genetically modified organisms (GMOs), enhanced crop characteristics like yield and stress tolerance, and aided in the creation of next-generation medicines, such as genetic cures for inherited illnesses like sickle cell anemia and cystic fibrosis, and tailored cancer treatments (Setti Sudharsan *et al*., 2025). In the meantime, CRISPR has given scientists the ability to precisely manipulate gene circuits and metabolic pathways in synthetic biology, allowing them to rewire biological activities. Pushing the limits of biological design, the technology is being incorporated into biosensors, programmable living systems, and synthetic gene networks (Sedlmayer *et al*., 2025). Furthermore, its applications have grown beyond basic gene disruption to include precise transcriptional control and programmable nucleotide conversion thanks to recent developments like CRISPRa/i (activation/interference), base editing, and prime editing (Lee *et al*., 2024). Because of this, CRISPR has emerged as a key component of contemporary bioengineering, fostering a new wave of biological research and translational uses. With an emphasis on its mechanistic underpinnings, technological advancements, and diverse range of applications, this study seeks to present a thorough examination of CRISPR's revolutionary significance in genetic biotechnology and synthetic biology (Usman *et al*., 2024). The main goal is to clarify how CRISPR-based systems are changing synthetic biological design, genome engineering, pharmaceutical development, and agricultural breakthroughs. The review is organized into several subject parts, starting with the molecular underpinnings of CRISPR-Cas systems and moving on to developments in genome editing methods, medical and agricultural applications, and, lastly, its incorporation into synthetic biology platforms. Future perspectives on ethical issues, regulatory obstacles, and next-generation CRISPR technologies are discussed in the review's conclusion.

Molecular Dynamics of CRISPR-Cas Systems, Biochemical Insights

Particularly when it comes to comprehending the mechanistic functions of Cas proteins, the molecular dynamics of CRISPR-Cas systems constitute an intriguing fusion of structural biology with biochemical accuracy (Bhattacharya *et al*., 2022). The capacity of Cas enzymes, particularly Cas9, Cas12, and Cas13, to identify, bind, and cleave target nucleic acids with exceptional precision is essential to CRISPR immunity and is mediated by well-calibrated structure-function interactions. Finding the protospacer adjacent motif (PAM), a brief DNA sequence that surrounds the target site, is one of the most important biochemical stages in target recognition. PAM recognition activates the DNA binding and cleavage properties of Cas proteins by causing a conformational change, particularly in the recognition (REC) and nuclease (NUC) lobes of Cas9. The process by which the guide RNA (gRNA) hybridizes with the complementary DNA strand, pushing out the non-target strand and stabilizing the complex, is known as R-loop creation (Shevchenko *et al*., 2025). The dynamic flexibility of Cas domains throughout this process has been demonstrated by structural investigations and molecular dynamics simulations, underscoring the ways in which hinge-like movements and interdomain interactions enable accurate R-loop propagation. This cascade ultimately results in coordinated DNA cleavage, where a double-strand break is produced when the HNH domain cleaves the target strand and the RuvC domain targets the non-target strand. Biochemical tests and cryo-EM investigations that show Cas protein conformations in various functioning states further enhance these mechanistic insights. The rational engineering of Cas variants for improved specificity, less off-target effects, and wider biotechnological uses is fueled by a molecular-level knowledge of these dynamic processes, which also helps us better understand CRISPR biology (Sindelar *et al*., 2024).



Fig 1: Molecular Dynamics of CRISPR-Cas Systems, Biochemical Insights

CRISPR Cloning Redefined: Beyond Double-Strand Breaks

Genetic biotechnology has been transformed with the introduction of CRISPR-based genome engineering, and new developments like as base editing and prime editing, are changing the game by making it possible to modify the genome precisely, programmably, and effectively without causing double-strand breaks

(Saber Sichani *et al.*, 2023). These next-generation technologies provide a DSB-free alternative to conventional CRISPR-Cas9 systems, which rely on DSBs followed by error-prone non-homologous end joining (NHEJ) or homology-directed repair (HDR). This greatly reduces unwanted insertions, deletions, and chromosomal rearrangements. To accomplish single-base conversions, such as cytosine to thymine or adenine to guanine, without rupturing the DNA backbone, base editing uses catalytically hindered Cas proteins (such as dCas9 or Cas9 nickase) linked with DNA deaminases. A Cas9 nickase attached to a reverse transcriptase (RT) and directed by a prime editing guide RNA (pegRNA), which both find the target site and encode the desired change, is used in prime editing, a more flexible and accurate technique (Mikhaylova *et al.*, 2024). The RT can transcribe the new DNA sequence straight onto the genome thanks to the molecular engineering of the pegRNA to incorporate an RT template and a primer binding site (PBS). Without the need for foreign donor DNA or DSBs, this sophisticated combination of targeted recognition and sequence rewriting enables insertions, deletions, and all 12 potential base substitutions. When combined, these advanced methods are broadening the biochemical toolset for safer and more accurate genome editing, with potential uses in synthetic biology, functional genomics, and pharmaceuticals (Zeng *et al.*, 2022).

Table 1: CRISPR Cloning Redefined: Beyond Double-Strand Breaks

Feature	Prime Editing	Base Editing	Explanation / Notes	References / Key Studies
Mechanism of Action	Cas9 nickase fused with reverse transcriptase (RT), guided by pegRNA	Cas9 nickase or dCas9 fused to cytidine/adenine deaminases	Prime editing writes new genetic information; base editing chemically alters single bases	Anzalone *et al.*, 2019; Komor *et al.*, 2016; Gaudelli *et al.*, 2017
DNA Breaks Required	No double-strand breaks (DSBs); single-strand nicking only	No DSBs; single-strand nicking optional	Both systems avoid DSB-associated cytotoxicity and error-prone repair	Increased safety profile for therapeutic applications
Type of Edits Possible	All 12 base substitutions, small insertions and deletions (indels)	Only C•G to T•A or A•T to G•C base conversions	Prime editing offers more versatility for complex edits	Base editing is limited in scope but highly efficient within its range
Editing Components	Cas9(H840A)-RT fusion protein + pegRNA (with PBS and RT template)	Cas9 nickase/dCas9 + cytidine deaminase (e.g., APOBEC1) or adenine deaminase (e.g., TadA) + sgRNA	pegRNA is multifunctional and engineered for precision	Deaminases perform chemical modifications without cutting
Target Window	Typically ~3–30 nucleotides downstream of PAM site	Usually 4–8 base editing window upstream of PAM	Target window for prime editing is more flexible	Base editing requires precise positioning of editable base
Dependency on DNA Repair Pathways	Minimal; does not rely on HDR or NHEJ	Base excision repair (BER) or mismatch repair pathways may influence outcomes	Prime editing is mostly self-sufficient	Base editing sometimes shows bystander edits due to repair processing
Off-target Effects	Generally lower than Cas9 nuclease; minimal indel formation	Possible off-target base conversions at unintended genomic and RNA sites	Optimization of pegRNA design reduces off-targets	Newer deaminase variants show improved specificity
Efficiency	Moderate to high, depending on cell type and locus	Very high in permissive systems and loci	Prime editing may have lower efficiency but broader scope	Base editing is extremely efficient but less flexible
Multiplexing Capability	Emerging; multiple edits possible with engineered pegRNAs	Well-established; multiple base edits using pooled sgRNAs	Both systems support parallel editing with improvements	Synthetic pegRNAs may enable complex combinatorial edits
Limitations	Larger cargo size for delivery; pegRNA design complexity	Cannot perform transversions or edits outside window	Delivery via viral vectors remains challenging	Trade-off between precision, efficiency, and cargo limitations
Delivery Systems	Electroporation, lipid nanoparticles, AAV (challenging due to size)	AAV, lentivirus, RNP delivery more established	Prime editor size exceeds AAV limit (~6.3 kb)	Dual-AAV strategies under development
RNA Off-targeting Risk	Very low	Some cytidine and adenine deaminases may target RNA	Base editing systems are being engineered to avoid RNA off-targets	TadA-8e variants show lower RNA editing
Clinical Potential	Promising for monogenic disorders, gene correction	Under evaluation for sickle cell disease, familial hypercholesterolemia, etc.	Prime editing may correct more complex genetic lesions	Base editing in trials (e.g., BEAM Therapeutics)

Notable Applications	Precise correction of point mutations, gene rescue in iPSCs	Treating point mutation diseases, functional genomics in vivo	Prime editing suited for gene therapy requiring complex edits	Base editing leads for blood disorders and eye diseases
Future Innovations	Improved pegRNA stability, better RT enzymes, and delivery methods	Smaller, more specific deaminases, expanded editing window	Both systems are expected to be combined with AI and delivery tech	Next-gen editors aim for single-cell precision

Epigenetic Engineering with CRISPR: Targeted Gene Regulation

CRISPR-enabled epigenetic engineering has become a game-changing strategy for targeted gene regulation, allowing for accurate control of gene expression without changing the underlying DNA sequence (Montenegro de Wit *et al*.,2020). The utilization of catalytically dead Cas9 (dCas9), which functions as a programmable DNA-binding scaffold when fused to different effector domains that alter the epigenetic landscape, is essential to this development. Researchers may generate locus-specific alterations of histones and DNA methylation patterns, which will switch genes on or off with great precision, by using specially engineered single-guide RNAs (sgRNAs) to direct dCas9 to specific genomic loci. To modify chromatin accessibility and transcriptional activity, biochemical approaches have evolved to incorporate dCas9 coupled with histone acetyltransferases (like p300), histone demethylases (like LSD1), or repressive domains like KRAB (Martella *et al*., 2021). Similar to this, site-specific modifications in cytosine methylation have been made possible by dCas9-based tools linked to DNA methyltransferases like DNMT3A or demethylases like TET1, opening the door to reversible control of gene activation or silencing. By making it easier to examine the causal links between gene activity and epigenetic markings, these technologies provide information on disease causes, developmental processes, and possible treatment approaches. Because dCas9 fusion systems are modular and particular, they may be designed to produce stable or temporary epigenetic modifications that are unique to the requirements of various biomedical applications. This holds great potential for synthetic biology and precision medicine (Weber *et al*., 2012).

Table 2: Epigenetic Engineering with CRISPR: Targeted Gene Regulation

Fusion Tool	Epigenetic Function	Target Modification	Biochemical Effector	Applications & Notes
dCas9-KRAB	Transcriptional repression	Histone deacetylation, H3K9me3 deposition	KRAB (Krüppel-associated box) repressor domain	Used to induce heterochromatin-like states, long-term gene silencing
dCas9-p300 Core	Transcriptional activation	Histone acetylation (H3K27ac)	p300 histone acetyltransferase (HAT) core	Promotes open chromatin; effective in gene upregulation, especially in enhancers
dCas9-VP64	Transcriptional activation	Indirect histone modification via coactivators	VP64 (4 tandem repeats of VP16 activation domain)	Widely used in synergistic activation strategies (e.g., SAM or SunTag systems)
dCas9-TET1	Epigenetic reprogramming, demethylation	5mC → 5hmC hydroxymethylation (DNA demethylation)	TET1 dioxygenase catalytic domain	Reverses aberrant methylation; applied in gene reactivation and cancer epigenetics
dCas9-DNMT3A	DNA methylation and transcriptional repression	Cytosine methylation (5mC)	DNMT3A (de novo DNA methyltransferase)	Enables locus-specific gene silencing, studies of DNA methylation causality
dCas9-LSD1	Transcriptional repression	Histone demethylation (H3K4me1/2)	LSD1 (lysine-specific demethylase 1)	Useful for enhancer silencing and repression of poised genes
dCas9-SunTag System	Signal amplification for activation/repression	Multi-effector recruitment (e.g., p300, VP64)	dCas9-GCN4 scaffold + scFv-effector fusion	Highly modular and tunable; enables multiplexed and amplified transcriptional control
dCas9-MQ1	Compact DNA methylation tool	5mC methylation	MQ1 (prokaryotic methyltransferase)	Smaller and more specific than DNMT3A; ideal for compact vector delivery systems
dCas9-SETDB1	Repressive histone methylation	H3K9me3 deposition	SETDB1 (SET domain bifurcated 1 methyltransferase)	Establishes stable gene silencing, particularly in retroelement regulation
dCas9-KDM4A	Transcriptional activation	H3K9me3 demethylation	KDM4A (histone demethylase)	Reverses silencing at heterochromatic loci, facilitates reactivation of silenced genes

Biochemical Optimization of Donor Template Design

A crucial tactic for improving the accuracy and effectiveness of homology-directed repair (HDR), a crucial process in CRISPR-based genome editing, is the biochemical optimization of donor template design (Jin *et al*., 2025). The chemistry, symmetry, and orientation of the donor template's molecules are among the key factors that determine HDR success. According to recent research, the performance of double-stranded DNA (dsDNA) templates and single-stranded oligodeoxynucleotides (ssODNs) can vary greatly depending on the sequence composition of the two and the presence of chemical modifications like phosphorothioate linkages, which shield the template from nuclease degradation. Furthermore, it has been demonstrated that asymmetrical designs are more successful than symmetrical templates with homology arms of equal length, especially those that are more in line with the normal DNA repair processes and have a longer homology arm on the PAM-distal side. Repair results are also influenced by template orientation; for example, greater integration rates are frequently obtained using templates complementary to the non-target strand (Shakirova *et al*., 2023). In addition to template design, increasing HDR fidelity and decreasing unwanted insertions or deletions (indels) caused by non-homologous end joining (NHEJ) can be achieved by adjusting the host cells' cell cycle phase, particularly synchronizing cells in the S and G2/M phases, when HDR is most active. Chemical inhibitors and modified cell cycle regulators that temporarily halt or guide cell populations into HDR-favorable periods have resulted from this. These biochemical techniques work together to provide a cohesive framework that improves cloning accuracy while also paving the way for future developments in therapeutic editing, precision genetic engineering, and synthetic biology applications (Abdi *et al*., 2024).

RNA-Targeting CRISPR Systems: CRISPR-Cas13 and Transcriptome Control

Transcriptome engineering and post-transcriptional gene regulation have become significantly more accessible thanks to RNA-targeting CRISPR technologies, especially those involving the Cas13 family (Granados-Riveron *et al*., 2018). CRISPR-Cas13 enzymes, such as Cas13a, Cas13b, Cas13d, and Cas13X, specifically recognize and cleave single-stranded RNA (ssRNA) under the guidance of a programmable CRISPR RNA (crRNA), in contrast to the extensively researched DNA-targeting Cas9 system. This enables precise, temporary, and reversible manipulation of RNA molecules without changing the genome. Cas13's catalytic activity is marked by its "collateral cleavage" behavior, in which binding of a target RNA triggers the nonspecific degradation of neighboring RNAs. This property has been creatively used for molecular diagnostics (e.g., SHERLOCK), but it also needs to be carefully controlled in therapeutic settings. Site-specific RNA editing, including adenosine-to-inosine (A-to-I) or cytidine-to-uridine (C-to-U) conversions, has been made possible by developments in building catalytically inactive Cas13 variants coupled with RNA-modifying enzymes, creating a potent toolkit for transcriptome editing. These RNA-editing technologies are currently being included in frameworks for RNA-centric synthetic biology to create dynamic regulatory circuits that regulate RNA localization, translation efficiency, and mRNA stability differently depending on the cell type (Nainar *et al*., 2016S). Further expanding its use beyond traditional gene editing, Cas13 systems are being used to investigate non-coding RNAs, analyze RNA-protein interactions, and modify viral RNAs in antiviral tactics. When taken as a whole, CRISPR-Cas13 systems mark a paradigm change toward transient, programmable, and adjustable transcriptome control, propelling a fresh wave of advancements in synthetic biology, RNA biology, and medicinal development (V'kovski *et al*., 2021).

Allosteric and Aptamer-Controlled CRISPR Systems

A revolutionary development in gene-editing technologies, the advent of allosteric and aptamer-controlled CRISPR systems allows for a new level of temporal and spatial accuracy in genome engineering (Tickner *et al*., 2021). Researchers may now conditionally activate or repress Cas nucleases in response to particular biochemical signals or light stimuli by combining ligand-responsive or optogenetic modules with the CRISPR/Cas machinery. In order to modulate the activity of Cas proteins or guide RNAs in real time, allosteric control entails designing them with sensor domains or aptamer-binding motifs that change conformation when they bind to certain ions, metabolites, or small molecules. An aptamer that binds to a chemical like theophylline or rapamycin, for example, can be tethered by ligand-responsive mechanisms to cause a structural change that either activates or inhibits Cas9 cleavage. Similarly, optogenetic methods use photosensitive domains, such as CRY2-CIB1 or LOV2, to regulate gene editing activities in a reversible and non-invasive manner by adjusting the dimerization, localization, or enzymatic activity of Cas proteins under particular light wavelengths (Manoilov *et al*., 2021). Because timing is crucial in developmental biology, synthetic biology circuits, and treatments, these biochemical techniques enable researchers to precisely target gene editing at certain times. Furthermore, combining these tactics with delivery methods or tissue-specific promoters improves targeted safety and accuracy even more, creating opportunities for context-dependent, programmable genome editing. With their unparalleled control, low off-target risks, and enhanced therapeutic viability, these emerging technologies have the potential to completely change the field of CRISPR applications (Li *et al*., 2021).

CRISPR Meets Synthetic Biology: Building Logic Circuits and Biosensors

Strong opportunities for creating programmable biological systems have been made possible by the combination of synthetic biology with CRISPR technology, particularly in the creation of logic circuits and biosensors (Hicks *et al*., 2020). Utilizing the programmability of CRISPR-Cas systems, CRISPR-based logic gates allow cells to analyze numerous inputs and carry out intricate decision-making activities that are similar to digital computation. Guide RNAs and Cas effectors, such dCas9 coupled with transcriptional activators or repressors, are employed in the building of these artificial logic circuits to regulate gene expression in response to certain chemical stimuli. This enables extremely selective and context-dependent genetic responses by enabling the generation of Boolean operations (AND, OR, NOT, NOR, etc.) within live cells. To include inputs from the intracellular or extracellular environment, these circuits use CRISPR-guided dynamic transcription modulation, RNA scaffolding, and tightly controlled promoter designs at the biochemical level (Joshi *et al*., 2024). This capacity serves as the foundation for sophisticated biosensors, in which CRISPR components identify ambient pollutants, metabolites, or illness indicators and translate their presence into measurable genetic outputs. To accomplish multiplex detection and real-time cellular diagnostics, these biosensors frequently combine several input-responsive components into a single integrated system, taking advantage of CRISPR's high specificity and programmability. Researchers are currently creating live sensors that may be used for precision bioengineering applications, pathogen surveillance, and therapeutic monitoring by coordinating biological logic with CRISPR's editing and transcriptional control capabilities (Zhou *et al*., 2024).

CRISPR and Organelle Editing: Mitochondrial and Chloroplast Genome Engineering

The manipulation of nuclear DNA has been transformed by CRISPR-based genome editing; nevertheless, there are substantial biochemical obstacles when it comes to editing non-nuclear genomes, such as those of mitochondria and chloroplasts (Srivastava *et al*., 2024). The delivery and operation of genome editing tools are complicated by these organelles' specific genetic codes, highly controlled protein import machinery, and distinctive double-membrane architectures. Since mitochondria and chloroplasts lack natural mechanisms to identify and import foreign RNA, one of the main obstacles is the effective import of guide RNAs and Cas proteins into these organelles. In order to get around this, scientists have created specialized Cas9 variants, notably transcription activator-like effector nucleases (TALENs) and mitochondrially targeted zinc-finger nucleases (mtZFNs), which have demonstrated potential in mitochondrial genome editing even in the absence of RNA guidance. More recently, creative methods have tried to design CRISPR systems that work with the mitochondrial matrix. For example, adding mitochondrial localization cues to Cas9 or other DNA-targeting proteins to improve import through the translocase complexes (Mullally *et al*., 2019). Targeting proteins and guaranteeing accurate homologous recombination—plastids' preferred repair mechanism-are also difficult tasks for chloroplasts. The utilization of synthetic biology technologies to boost transformation efficiency and chloroplast transit peptides to direct Cas proteins into plastids has been the main area of research. Organelle genome editing is still in its infancy despite these developments, and further biochemical optimization is required to address problems with off-target effects, restricted DNA repair pathways, and the organellar membranes' inability to let RNA molecules pass through. These obstacles highlight the intricacy of non-nuclear genome engineering and necessitate multidisciplinary advancements that integrate nanotechnology, synthetic biology, and biochemistry (Pereira *et al*., 2017).

Engineering Cas Enzymes: Directed Evolution and Rational Design

The biochemical landscape of gene editing has been completely transformed by the engineering of CRISPR-associated (Cas) enzymes through directed evolution and logical design, opening up previously unheard-of levels of accuracy, efficiency, and flexibility (Kumari *et al*., 2025). The deliberate improvement of Cas enzyme fidelity, specificity, and catalytic activity—all crucial for reducing off-target effects and increasing therapeutic applicability—is at the core of this invention. A wider range of host systems and circumstances may now be served by Cas variants with enhanced cleavage specificity and temperature stability thanks to directed evolution, which was made possible by successive rounds of mutagenesis and high-throughput screening. In the meanwhile, Cas functional domains may be precisely tuned to maximize PAM recognition, DNA binding, and nuclease kinetics thanks to a logical design that is guided by high-resolution structural and computational insights. Additionally, by combining programmable Cas scaffolds with various functional moieties, modular Cas architectures have made it easier to create multifunctional gene tools such as base editors, prime editors, transcriptional regulators, and epigenetic modulators (Goell *et al*., 2021). Because of the plug-and-play design framework provided by these designed platforms, Cas systems may be tailored for specific genomic modifications, synthetic biology circuits, and diagnostic applications. When combined, evolutionary and rational design techniques improve the performance of Cas enzymes and increase their applicability in a variety of medicinal and biotechnological fields (Dinmukhamed *et al*., 2021).

FUTURE DIRECTIONS

The smooth fusion of multi-omics, CRISPR biochemistry, and artificial intelligence (AI) is set to revolutionize genetic biotechnology in the future

(Biswas *et al*., 2023). Through the use of deep learning and extensive genomic information, artificial intelligence (AI) has become a key player in the optimization of guide RNA (gRNA) design, increasing on-target efficiency while reducing off-target impacts. These AI-powered prediction models are getting more complex and can now adjust CRISPR activity with previously unheard-of accuracy by taking into consideration chromatin accessibility, epigenetic markers, and even three-dimensional genomic architecture. Concurrently, real-time, system-wide feedback loops that can iteratively improve CRISPR-based treatments have become possible because of the emergence of multi-omics, which integrates genomics, transcriptomics, proteomics, metabolomics, and epigenomics. To create an adaptable, self-optimizing system, transcriptomic and proteomic responses after genome editing, for example, can be input back into AI models to dynamically modify the expression of CRISPR components or recalibrate gRNA design. In addition to offering the potential to enhance editing specificity and cellular compatibility, these integrative methods also make it possible for precision medicine to employ customized treatment approaches, in which patient-specific multi-omic data direct customized CRISPR interventions. In the future, this collaboration will also help create context-aware CRISPR tools that react sensibly to environmental stress, disease cues, or cellular conditions, which will ultimately result in safer and more efficient uses in synthetic biology, gene therapy, and regenerative medicine.

CONCLUSION

CRISPR cloning's biochemical future lies at the nexus of system-wide programmability, catalytic innovation, and molecular precision. The development of CRISPR technologies has been largely driven by a growing knowledge of the molecular processes that control DNA repair pathways, RNA specificity, and nuclease activity. The development of increasingly sophisticated and manageable CRISPR systems has been aided by fundamental discoveries about the conformational dynamics of Cas enzymes, PAM recognition, and off-target kinetics. By taking use of the underlying enzymatic flexibility and repair circuitry of host cells, emerging biochemical techniques—such as prime editing, base editors, and tailored Cas variants—are not only increasing the range of genomic changes but also improving their precision and efficiency. In the future, a next-generation CRISPR toolkit that is modular, programmable, and extremely versatile across a variety of organisms and cellular contexts is anticipated through the combination of computational protein design, high-throughput biochemical screening, and synthetic biology. This convergence simplifies the design-build-test cycle in genome engineering by enabling the customisation of CRISPR components in silico prior to in vitro implementation. The ultimate goal of CRISPR cloning is to turn it from a potent gene-editing tool into a flexible molecular programming language that can be used to precisely and biochemically manipulate complex genetic circuits, epigenetic modifications, and therapeutic interventions.

REFERENCES

- Abdi, G., Patil, N., Tendulkar, R., Dhariwal, R., Mishra, P., Tariq, M., ... & Mudgal, G. (2024). Engineering Genomic Landscapes: Synthetic Biology Approaches in Genomic Rearrangement. In *Advances in Genomics: Methods and Applications* (pp. 227-264). Singapore: Springer Nature Singapore.
- Albayati, S. H., Nezhad, N. G., Taki, A. G., & Abd Rahman, R. N. Z. R. (2024). Efficient and feasible biocatalysts: Strategies for enzyme improvement. A review. *International Journal of Biological Macromolecules*, 133978.
- Alekseeva, I. V., & Kuznetsov, N. A. (2023). Historical aspects of restriction endonucleases as intelligent scissors for genetic engineering. *Fermentation*, *9*(10), 874.
- Ali, F., Hameed, A., Rehman, A., Sarfraz, S., Rajput, N. A., & Atiq, M. (2024). CRISPR System Discovery, History, and Future Perspective. *OMICs-based Techniques for Global Food Security*, 159-170.
- Aslam, M. A., Hammad, M., Ahmad, A., Altenbuchner, J., & Ali, H. (2021). Delivery methods, resources and design tools in CRISPR/Cas. *CRISPR Crops: The Future of Food Security*, 63-116.
- Bhattacharya, S., & Satpati, P. (2022). Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. *ACS omega*, *8*(2), 1817-1837.
- Biswas, A., Kumari, A., Gaikwad, D. S., & Pandey, D. K. (2023). Revolutionizing biological science: The synergy of genomics in health, bioinformatics, agriculture, and artificial intelligence. *OMICS: A Journal of Integrative Biology*, *27*(12), 550-569.
- Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., ... & Zhuang, X. (2022). High-content CRISPR screening. *Nature Reviews Methods Primers*, *2*(1), 1-23.
- Dinmukhamed, T., Huang, Z., Liu, Y., Lv, X., Li, J., Du, G., & Liu, L. (2021). Current advances in design and engineering strategies of industrial enzymes. *Systems Microbiology and Biomanufacturing*, *1*, 15-23.
- Goell, J. H., & Hilton, I. B. (2021). CRISPR/Cas-based epigenome editing: advances, applications, and clinical utility. *Trends in Biotechnology*, *39*(7), 678-691.
- Granados-Riveron, J. T., & Aquino-Jarquin, G. (2018). CRISPR–Cas13 precision transcriptome engineering in cancer. *Cancer research*, *78*(15), 4107-4113.

- Hicks, M., Bachmann, T. T., & Wang, B. (2020). Synthetic biology enables programmable cell-based biosensors. *ChemPhysChem*, *21*(2), 132-144.
- Irfan, M., Majeed, H., Iftikhar, T., & Ravi, P. K. (2024). A review on molecular scissoring with CRISPR/Cas9 genome editing technology. *Toxicology Research*, *13*(4), tfae105.
- Jin, Y. Y., Zhang, P., & Liu, D. P. (2025). Optimizing homology-directed repair for gene editing: the potential of single-stranded DNA donors. *Trends in Genetics*.
- Joshi, S. H. N., Jenkins, C., Ulaeto, D., & Gorochowski, T. E. (2024). Accelerating Genetic Sensor Development, Scale-up, and Deployment Using Synthetic Biology. *BioDesign Research*, *6*, 0037.
- Kumari, N., Aryan, S., Sharma, N. R., Choudhary, N., Choudhary, S., & Sharma, P. (2025). *Recent Trends and Innovations in Entomology*. Crown Publishing.
- Lee, H., & Kim, K. (2024). Recent Research Trends in Stem Cells Using CRISPR/Cas-Based Genome Editing Methods. *International Journal of Stem Cells*, *17*(1), 1-14.
- Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020). Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. *Signal transduction and targeted therapy*, *5*(1), 1.
- Madhiyazhagan, P. (2024). Advances in Instrumentation for Biological Sciences: Unveiling the Secrets of Life. *Advance Research Trends in Biology*, 44.
- Manoilov, K. Y., Verkhusha, V. V., & Shcherbakova, D. M. (2021). A guide to the optogenetic regulation of endogenous molecules. *Nature methods*, *18*(9), 1027-1037.
- Martella, A., & Fisher, D. I. (2021). Regulation of gene expression and the elucidative role of CRISPR-based epigenetic modifiers and CRISPR-induced chromosome conformational changes. *The CRISPR Journal*, *4*(1), 43-57.
- Mikhaylova, E. V., Kuluev, B. R., Gerashchenkov, G. A., Chemeris, D. A., Garafutdinov, R. R., Kuluev, A. R., ... & Chemeris, A. V. (2024). Prime-editing methods and pegRNA design programs. *Molecular Biology*, *58*(1), 17-32.
- Montenegro de Wit, M. (2020). Democratizing CRISPR? Stories, practices, and politics of science and governance on the agricultural gene editing frontier. *Elem Sci Anth*, *8*, 9.
- Mullally, G. (2019). *The engineering and evaluation of genome editing tools in mitochondria* (Doctoral dissertation, University of Bristol).
- Nainar, S., Marshall, P. R., Tyler, C. R., Spitale, R. C., & Bredy, T. W. (2016). Evolving insights into RNA modifications and their functional diversity in the brain. *Nature neuroscience*, *19*(10), 1292-1298.
- Nazipova, N. N., & Shabalina, S. A. (2020). Understanding off-target effects through hybridization kinetics and thermodynamics. *Cell Biology and Toxicology*, *36*, 11-15.
- Pereira, C. V., & Moraes, C. T. (2017). Current strategies towards therapeutic manipulation of mtDNA heteroplasmy. *Frontiers in Bioscience (Landmark edition)*, *22*, 991.
- Saber Sichani, A., Ranjbar, M., Baneshi, M., Torabi Zadeh, F., & Fallahi, J. (2023). A review on advanced CRISPR-based genome-editing tools: base editing and prime editing. *Molecular Biotechnology*, *65*(6), 849-860.
- Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018). Synthetic gene circuits for the detection, elimination and prevention of disease. *Nature biomedical engineering*, *2*(6), 399-415.
- Setti Sudharsan, M., Madhumitha, L., Keerthi, V., Venkatesan, N., Pazhamalai, V., Hari, S., ... & Ivo Romauld, S. (2025). Genetic Engineering for Improving Quality, Productivity, and Value of Industrial Crops. In *Industrial Crops Improvement: Biotechnological Approaches for Sustainable Agricultural Development* (pp. 21-39). Cham: Springer Nature Switzerland.
- Shakirova, A., Karpov, T., Komarova, Y., & Lepik, K. (2023). In search of an ideal template for therapeutic genome editing: A review of current developments for structure optimization. *Frontiers in genome editing*, *5*, 1068637.
- Shevchenko, E., Laufer, S., Poso, A., & Kronenberger, T. (2025). Drug Design in Motion: Concepts and Applications of Classical Molecular Dynamics Simulations. *Computer-Aided and Machine Learning-Driven Drug Design: From Theory to Applications*, 199-242.
- Sindelar, R. D. (2024). Genomics, other “OMIC” technologies, precision medicine, and additional biotechnology-related techniques. In *Pharmaceutical Biotechnology: Fundamentals and Applications* (pp. 209-254). Cham: Springer International Publishing.
- Srivastava, A., Joshi, M., & Rengan, A. K. (2024). Feeding the future: the role of nanotechnology in tailored nutrition. *The Nucleus*, 1-15.
- Tickner, Z. J., & Farzan, M. (2021). Riboswitches for controlled expression of therapeutic transgenes delivered by adeno-associated viral vectors. *Pharmaceuticals*, *14*(06), 554.
- Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR gene therapy: applications, limitations, and implications for the future. *Frontiers in oncology*, *10*, 1387.
- Usman, M. (2024). The Impact of Synthetic Biology on Genetic Research and Biotechnology. *Frontiers in Biotechnology and Genetics*, *1*(2), 107-125.

- V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. *Nature Reviews Microbiology*, *19*(3), 155-170.
- Wang, Z., Qi, X., Ren, X., Lin, Y., Zeng, F., & Wang, Q. (2025). Synthetic evolution of Saccharomyces cerevisiae for biomanufacturing: Approaches and applications. *mLife*, *4*(1), 1-16.
- Weber, W., & Fussenegger, M. (2012). Emerging biomedical applications of synthetic biology. *Nature Reviews Genetics*, *13*(1), 21-35.
- Zeng, Y., Hong, Y., Azi, F., Liu, Y., Chen, Y., Guo, C., ... & Xu, P. (2022). Advanced genome-editing technologies enable rapid and large-scale generation of genetic variants for strain engineering and synthetic biology. *Current Opinion in Microbiology*, *69*, 102175.
- Zhou, L., & Simonian, A. L. (2024). CRISPR/Cas Technology: The Unique Synthetic Biology Genome-Editing Tool Shifting the Paradigm in Viral Diagnostics, Defense, and Therapeutics. *Annual Review of Biomedical Engineering*, *26*.